Investment & Fund Management
Sanifit needed substantial
Full Credential Description
Sanifit, a clinical-stage biopharmaceutical company based in Spain, faced significant challenges in developing an experimental drug aimed at treating cardiovascular diseases associated with calcification in patients with renal insufficiencies undergoing haemodialysis. Founded in 2007 as a spin-off from the University of the Balearic Islands, Sanifit needed substantial funding to advance its research and clinical trials.
To address these challenges, Sanifit initially secured an EU grant in 2010, which was pivotal in validating their research and attracting further investment. This initial funding allowed the company to demonstrate the viability of their approach, which focuses on managing calcium distribution in the body to mitigate cardiovascular risks in patients with renal issues. In 2015, Sanifit received a significant equity investment from Ysios Capital, a Spanish venture capital firm supported by the European Investment Fund (EIF) under the EUs Investment Plan for Europe. This investment enabled Sanifit to expand its team from just four employees to approximately 22, facilitating the funding of phase II clinical trials.
As a result of these investments, Sanifit transitioned from a small, local company to an international player, recently establishing new facilities in the United States. The company anticipated phase II trial results in early 2018 for a first orphan indication, with plans for phase III trials to follow, potentially leading to the drug's market availability shortly thereafter. This strategic funding and growth trajectory exemplify how targeted financial support can significantly impact the development of innovative healthcare solutions.